PRELOAD PRELOAD PRELOAD PRELOAD PRELOAD

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

With three FDA-approved products on the market and a fully-integrated multinational organization in place, BioMarin is providing innovative therapeutics to patients with serious unmet medical needs.

LATEST NEWS

  • Results From Investigator-Sponsored Trials Presented at SSIEM Conference...  MORE >
  • BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease...  MORE >
  • BioMarin Acquires ZyStor Therapeutics, Inc....  MORE >